2/12
07:00 am
mcrb
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
High
Report
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
2/6
06:36 pm
mcrb
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
Low
Report
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
1/6
07:00 am
mcrb
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Low
Report
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy